Periodontitis is one of the most common inflammatory diseases, with a prevalence of 11% worldwide for the severe forms and an estimated heritability of 50%. The disease is characterized by destruction of the alveolar bone due to an aberrant host inflammatory response to a dysbiotic oral microbiome. Previous genome-wide association studies (GWAS) have reported several suggestive susceptibility loci. Here, we conducted a GWAS using a German and Dutch case-control sample of aggressive periodontitis (AgP, 896 cases, 7,104 controls), a rare but highly severe and early-onset form of periodontitis, validated the associations in a German sample of severe forms of the more moderate phenotype chronic periodontitis (CP) (993 cases, 1,419 controls). Positive findings were replicated in a Turkish sample of AgP (223 cases, 564 controls). A locus at SIGLEC5 (sialic acid binding Ig-like lectin 5) and a chromosomal region downstream of the DEFA1A3 locus (defensin alpha 1-3) showed association with both disease phenotypes and were associated with periodontitis at a genome-wide significance level in the pooled samples, with P ¼ 1.09E-08 (rs4284742,-G; OR ¼ 1.34, 95% CI ¼ 1.21-1.48) and P ¼ 5.48E-10 (rs2738058,-T; OR ¼ 1.28, 95% CI ¼ 1.18-1.38), respectively. SIGLEC5 is expressed in various myeloid immune cells and classified as an inhibitory receptor with the potential to mediate tyrosine phosphatases SHP-1/-2 dependent signaling. Alpha defensins are antimicrobial peptides with expression in neutrophils and mucosal surfaces and a role in phagocyte-mediated host defense. This study identifies the first shared genetic risk loci of AgP and CP with genome-wide significance and highlights the role of innate and adaptive immunity in the etiology of periodontitis.
Introduction
Periodontitis (PD) is among the most common inflammatory diseases, affecting human populations at worldwide prevalence rates of 11% for the severe forms (1). It is the major cause of tooth loss in adults above 40 years (2) . A microbial shift of the oral microbiota is considered to trigger the inflammatory reaction and long-term smoking and diabetes add to the disease risk. The inflammation leads to gingival bleeding, gingival pocket formation and to the resorption of alveolar bone, which withdraws from the site of inflammation, a process that eventually causes tooth loss. These steps are unique in the pathogenesis of complex diseases, because the oral cavity is the only part of the human organism where, in an intricate environment of microbes, soft tissues like the gingival mucosa dynamically interact with hard tissues like teeth and skeletal bone. However, the precise molecular mechanisms that drive the individual steps in the pathogenesis of PD are currently unknown. The different phenotypes of PD can be considered as different parts of a large range of similar conditions, which can be attributed to the effects of different combinations of genetic risk loci, which form the individual genetic constitution. This genetic constitution determines the immune response, which is challenged by internal and external factors like the biofilm, smoking, stress, age, excess dietary fat and diabetes. In this view, different disease manifestations are not confined entities but share risk alleles and covariates. Nevertheless, the current study uses samples classified as aggressive and chronic periodontitis, in accordance with the current classification for PD. Aggressive periodontitis (AgP) is a rare disease phenotype with a prevalence of $ 0.1% in European Caucasians (3) . The diagnosis is based on severe periodontal attachment loss and severe destruction of the alveolar bone in adolescents and young adults (< 35 years of age). Because of the usually very young age of disease onset, the absence of risk factors like long-term smoking or diabetes, often paralleled by the absence of plaque, it is considered that largely unknown genetic risk variants play a strong role in disease onset and progression of AgP. Unraveling the genetic architecture of AgP may help to understand the molecular mechanisms that underlie the disease risk of PD.
We earlier performed a genome-wide association study (GWAS) of AgP with 438 cases and 1,320 controls on the Affymetrix 500K Genotyping System and identified a single nucleotide polymorphism (SNP) within the gene GLT6D1 to be associated with AgP at a genome-wide significance level (4) , which was later replicated in a sub-Saharan population from Sudan (5) . GWAS that focused on chronic periodontitis (CP) suggested various risk variants but have hitherto failed to give clear statistical evidence for association (6) (7) (8) (9) (10) (11) (12) . This is partly due to the high heterogeneity of CP and the important contributions of confounding risk factors such as smoking and diabetes, but mostly relates to the limited statistical power of these GWAS. We now expand the GWAS in a sample of 896 AgP cases and 7,104 controls from Germany (GER) and The Netherlands (NL), validated the most significant associations in a GWAS of 2,211 German CP cases and 1,817 controls (6) , and replicated the variants that were shared between AgP and CP in an independent AgP sample from Turkey (220 cases, 550 controls). Our data give novel insights into the molecular mechanisms of both forms of PD.
Results

Discovery stage
We performed two GWAS in a sample of 717 AgP cases and 4,213 controls from GER, and a sample of 179 AgP cases and 2,891 controls from NL. After the QC steps, we retained 502,332 intersecting autosomal SNPs in 680 cases and 3,973 controls in GER, and 554,855 intersecting autosomal SNPs in 171 cases and 2,607 controls in NL. To combine the dissenting SNP sets, to fillin missing data and to detect genotyping errors, we imputed genotypes based on reference haplotypes from 1000 Genomes Phase 3. Both GWAS studies were combined in a meta-analysis with association data for 5,870,152 genotyped or imputed autosomal SNPs. Multidimensional scaling showed minimal evidence for population stratification in GER and NL after removal of outliers in the QC procedures (Supplementary Material, Figs S1 and S2). According to the quantile-quantile plots, the distribution of observed P values deviated from expected P values only in the extreme tail (Supplementary Material, Fig. S3 ). Genomic inflation factors (k) for SNPs were 1.05 and 1.02 for GER and NL, respectively, and 0.97 for the two studies combined, indicating population stratification effects were negligible. In the discovery stage, 16 distinct loci surpassed our preassigned selection criteria (Table 1 , Supplementary Material, Figs S1-S4).
Adjustment for (i) no covariates, (ii) sex, (iii) smoking status, (iv) MDS components, and (v) all covariates showed only small (maximal up to power of ten) variation of the P values in the discovery stage for all top SNPs. This indicates that the covariates only have a minor influence on the level of association (Table 1,  Supplementary Material, Table S1 ).
Validation with CP
16 lead SNPs of the discovery stage were taken forward to validation in 993 German CP cases and 1,419 controls, using imputed genotype data of a GWAS of CP (6) . Three SNPs at two loci showed association with CP (Table 1 , Fig. 1 ). At the DEFA1A3 locus (13), AgP GWAS leads SNP rs2978951, and additionally rs2738058, which was previously found to be associated with CP (6) The top SNPs at both loci were in low LD with other highly associated variants, suggesting multiple causal variants. However, in the validation step we were only able to validate rs2738058 at DEFA1A3, because the SNPs were either not included in CP or the OR strongly deviated from AgP-GER-NL resulting in larger P values (Fig. 1) . To fully assess whether rs2978951 and rs2738058 are independent variants, we performed a conditional analysis with AgP-GER and AgP-NL using an additive (add), genotypic (gen), recessive (rec), dominant (dom) and heterozygous (het) conditioning model (Supplementary Material, Table S5 ). According to the P values of AgP-GER, independence of the two SNPs was only observed for the het model. SNP rs2978951 had a level of significance of P ¼ 1.79 Â 10 À06 before and P ¼ 1.61 Â 10
À06
after conditioning on SNP rs2738058, while the OR and 95% CI remained constant. The P value for NL slightly decreased from P ¼ 2.37 Â 10 À02 to P ¼ 2.80 Â 10
À02
. Conditioning with models add, dom, rec and gen decreased the P value up to P ¼ 4.46 Â 10 À03 (add) in GER and increased it in NL (P ¼ 6.45 Â 10
Meta-analysis of AgP and CP. The subsequent meta-analysis, which included the AgP discovery and the CP replication sample comprised 1,844 cases and 8,255 controls. It showed genomewide significant evidence of association for the GWAS lead SNPs at DEFA1A3 and SIGLEC5 (Supplementary Material, Table S1 ). For the other suggested AgP associations, the nonfindings in the meta-analysis may be caused by a lack of statistical power of the CP sample, resulting in a false negative finding. Accordingly, no conclusion on a potential role for the etiology of CP can be drawn for these SNPs.
Replication in a Turkish AgP sample
We replicated the associations of the 15 SNPs, which were validated with CP, in an additional AgP case-control sample of Turkish descent (Supplementary Material, Table S1 ). In this sample, SNP rs1122900 at SLC1A3 showed nominal significant (i.e. P < 0.05) association with P ¼ 0.0137 with the same effect direction (OR ¼ 1.32, 95% CI ¼ 1.06-1.65). After pooling with the AgP discovery sample, the association level of rs1122900 was P ¼ 8 Â 10 Table 2 ), i.e. stronger compared to its association with the discovery sample alone (P ¼ 1.77 Â 10
À05
) and also compared to the association of the GWAS lead SNP rs6887423 in the discovery sample (P ¼ 1.42 Â 10
À06
). The other 16 loci showed no individual association with AgP in the small Turkish sample. However, the ORs of multiple SNPs was consistent with ORs in the discovery and resulted in stronger associations after pooling with the AgP discovery sample (Tables 1 and 2 ).
Meta-analysis of all samples
The final meta-analysis included all AgP samples and the CP validation samples. Here, the DEFA1A3 SNPs rs2978951 and rs2738058 reached genome-wide significance with P ¼ 2. 
Expression quantitative trait locus (eQTL) mapping
Examination of the 16 distinct haplotype blocks that suggested association with AgP for expression quantitative trait loci (QTLs) indicated cis-and trans-regulatory effects for various SNPs (Table 3 , Supplementary Material, Table S6 ).
Of the SNPs that showed genome-wide significant association in the meta-analysis, SNP rs2738058 at DEFA1A3 and rs2977793, which tags GWAS lead SNP rs2978951 at DEFA1A3 (r 2 ¼ 0.8) both show eQTL effects on DEFA4, with P ¼ 1.7 Â 10 À03 and 3.9 Â 10 À05 , respectively. However, these SNPs map between the pseudogenes DEFA9P and DEFA10P, 5 kb downstream of DEFA4, which are expressed in blood at low levels (GTEx data). Additionally, rs4284742 at SIGLEC5 showed a cis-effect on the transcription level of SIGLEC5 with P ¼ 7.7 Â 10 À14 in whole blood, indicating SIGLEC5 to be the affected gene of this association.
Experimental data showed that SIGLEC5 efficiently inhibits FCER1G mediated calcium fluxing (14) . FCER1G was one of the 17 risk loci, which were tagged by SNPs that surpassed our preassigned selection criteria. In the AgP discovery sample, rs2070901, which is located 30 base pairs upstream of the first exon of FCER1G, showed an association with P ¼ 9.45 Â 10 À06 , OR ¼ 1.31 (95% CI ¼ 1.16-1.47). eQTL data of this SNP suggested a cis-effect on the expression of FCER1G (P ¼ 9.16 Â 10
À16
) in whole blood. However, the most significant effect of rs2070901 was reported to act in trans on the expression of B4GALT3 (P ¼ 8.43 Â 10
À26
). B4GALT3 expression alters glycosylation and expression of the N-glycan of b1 integrin (ITGB1) (15) . SNP rs2144815, another of the 16 GWAS lead SNPs that surpassed our preassigned selection criteria with P ¼ 1.35 Â 10
À06
, OR ¼ 1.39 (95% CI ¼ 1.22-1.59) is located within exon 3 of the long noncoding RNA (lncRNA) RP11-725G5.2. According to GTEx, rs2144815 has a ciseQTL effect on RP11-725G5.2 (9.86 Â 10
À11
) in testis and according to GRASP v2 a trans-eQTL effect on ITGB1 expression in peripheral blood monocytes (P ¼ 1.22 Â 10 À06 ). No additional eQTL effect of rs2144815 was reported to date. For SNP rs1122900 at SLC1A3, a cis-eQTL effect for the antisense lncRNA CTD-2353F22.1 (P ¼ 2.9 Â 10 À07 ) in lymphocytes was reported in GTEx, which overlaps with the 3' end of SLC1A3.
Cis genes DEFA1A3, SIGLEC5, FCER1G and CTD-2353F22.1 belong to the same topologically associating domains (TAD, i.e genomic regions defined by interactome boundaries that are mainly cell-type independent), as their linked SNP (Supplementary Material, Table S7 ) (16) .
Relationship with other traits
Among the 16 lead SNPs and their nine neighboring SNPs, which were examined in our analyses, only SNP rs2738058 at the DEFA1A3 locus has a genome-wide significant association with another trait (IgA nephropathy, P ¼ 2 Â 10 À27 , OR¼ 1.27, 95% CI ¼ 1.21-1.32, Supplementary Material, Table S8 ). Moreover, the same SNP was earlier reported as a suggestive risk variant of CP, in the same cohort we used in our validation, before (6) . Further associations were related to plasminogen levels (rs4284742), cholesterol (rs17340482, rs4284742), triglycerides (rs17340482), blood pressure (top SNPs rs17340482, rs2978951), arthritis (rs2978951, rs4284742), obesity (rs2070901, rs3830904, rs11382193, rs11633566, rs3830904), cardiac diseases (rs17340482, rs744280), bone (rs1002204), and psychologic disorders (rs3830904, rs6137428, rs1002204, rs11382193, rs3830904). None of the traits was directly related to smoking. A genetic correlation analysis with AgP-GER-NL and 219 other traits showed positive correlations especially to metabolic traits (Supplementary Material, Table S9 ).
Discussion
The current study identified PD risk loci at SIGLEC5 and DEFA1A3 with genome-wide significance. The various disease phenotypes of PD are part of a large range of similar conditions that are attributed to the effects of different combinations of *P-value got smaller in pooled analysis using AgP cohorts only.
Result of the unadjusted association tests are shown in Supplementary Material, Table S1 .
genetic variants and environmental factors. In this view, AgP, the most severe and early-onset form of PD, would be affected to a higher degree by genetic risk factors, whereas we consider that CP, which is characterized by a late age of disease-onset, would lack variants with high penetrance, but would be affected stronger by the accumulating negative effects of environmental factors and ageing. Yet, both disease phenotypes, which essentially differ in the speed of progression but not in the clinical picture of alveolar bone loss, share genetic and environmental risk factors. We aimed to elucidate the underlying genetic risk factors of AgP to enhance the current etiological concept. The risk variant rs2738058, located at the intergenic region that separates the antimicrobial peptides DEFA1 and DEFA4 was suggested as a risk allele for CP in a GWAS before (6) . These genes belong to the family of alpha defensins that cluster on chromosome 8 and likely play a role in phagocyte-mediated host defense against bacteria, fungi and viruses. The genes DEFA1 and DEFA3 are highly copy-variable and differ only by a single base substitution in the coding sequence. They seem to be interchangeable occupants of a 19 kb long copy-variable repeat unit, with both DEFA1 and DEFA3 gene number showing variation (17) . For this reason, the composite designation DEFA1A3 was suggested (13) . Additionally, some pseudogenes were annotated at this region, but their biological function has yet remained unknown. It is believed that the variability in defensin gene copy numbers could contribute to differences in individual resistance to infections (18) . DEFA1A3 and DEFA4 are strongly expressed in neutrophils and macrophages, as well as in the epithelia of mucosal surfaces. eQTL analysis suggested a regulatory effect of the rs2738058 on DEFA4. However, further studies are needed to characterize the proposed regulatory role of rs2738058 on DEFA4 and DEFA1A3 expression and also the context of the observed association with copy number variation.
SIGLEC5 (CD170) is a member of the human CD33-related siglecs and is broadly expressed in various myeloid cells of the innate immune system and in B cells (19) . Siglec 5 is classified as an inhibitory receptor with the potential to mediate tyrosine phosphatases SHP-1 and -2 dependent signaling (14) . It was suggested that the interaction of Siglec 5 and SHP-1 and -2 could be important in maintaining leukocytes in the quiescent state until activation is triggered via appropriate receptors. Accordingly, SIGLEC5 seems to modulate the activation of myeloid cells to prevent inappropriate reactivity against self-tissues, as recently reviewed (20) . The ability to distinguish foreign pathogens from self and to make an appropriate response is essential to avoid bystander damage to host cells. In this context, we point out that an important feature in the pathogenesis of AgP are repeating periods of severe inflammation, which eventually lead to extensive resorption of the alveolar bone. The inflammation often is not accompanied by obvious signs of a particular pathogenic burden such as increased oral plaque, which could reflect an aberrant reactivity of the immune system to yet unknown triggers or intolerance to resident oral bacteria.
The homeostasis of the skeletal bone depends on the balance between bone formation by osteoblasts and bone resorption by osteoclasts. Interestingly, SIGLEC5 was shown to efficiently inhibit FCeRI-mediated activation (14) . FCER1G (Fc Fragment of IgE Receptor Ig) encodes the gamma subunit of FCeRI and was among the 17 loci, which showed association with AgP with P < 10 À06 in our GWAS. FCeRI is the high-affinity receptor for the Fc region of immunoglobulin E (IgE), found on epidermal Langerhans cells, mast cells, eosinophils and basophils, and is part of signaling cascades that induce proinflammatory cytokine expression (21) . It was shown in vitro that the osteoclast-associated receptor OSCAR associates with FCER1G, and in the mouse model it was experimentally demonstrated that mice lacking FCER1G exhibit severe osteopetrosis owing to impaired osteoclast differentiation (22) . From these studies, it was concluded that FCER1G is an essential constituent for the maintenance of bone homeostasis and it is essential for differentiation of osteoclasts. Another recent study demonstrated that OSCAR is involved in activation of human dendritic cells (23) and enhances the proinflammatory responses of human monocytes and neutrophils (24) . In this context, it is tempting to speculate that FCER1G may couple bone resorption to signals of the immune system. We also observed SNP rs6887423, located downstream to the glutamate transporter gene SLC1A3 (GLAST-1), to be strongly associated with AgP in the German-Dutch discovery sample and to be associated with borderline significance with the small Turkish AgP sample. This SNP showed no association with the CP sample. Larger replication studies are needed to give clear statistical evidence for this association. However, SLC1A3 is an interesting candidate. Glutamate signaling is implicated in the bone in transmission and response to mechanical stimuli of the environment (25) . SLC1A3 is constitutively expressed in bone forming osteoblasts and in osteocytes and it is inhibited by mechanical loading of these cells (26, 27) . It is further genome-wide associated with vertebral osteoporosis phenotypes (28) .
It is likely that the limitations of the statistical power in our Turkish AgP sample and the CP sample resulted in inability to replicate all relevant signals and that we missed true positive signals. Larger replication samples are needed to fully validate all the signals that were suggested by our explorative study.
In conclusion, of the 17 loci, which showed associations with AgP at a significance level of P < 10 À05 in the explorative study, DEFA1A3 and SIGLEC5 are associated at a genome-wide significance level in the pooled AgP and CP samples, providing statistical evidence for the relevance of these loci in the etiology of PD. We further suggest the FCER1G and SLC1A3 as promising candidates for future association studies in larger case-control samples. 
Materials and Methods
Study population
We give a detailed description of the study populations that were included in the discovery stage in Supplementary Material, Tables S10 and S11. AgP cases and controls. In the discovery stage, we used a German and a Dutch case-control sample of AgP. The German sample consisted of 717 AgP cases (302 males and 415 females) who were recruited across Germany by the biobank Popgen (29), University-Hospital Schleswig-Holstein, Germany, and previously described (30) . The German control sample consisted of 4,213 individuals (2,018 males, 2,191 females, four unknown) from North-and West-Germany. They were recruited from the Competence Network "FoCus -Food Chain Plus" (31), the Dortmunder Gesundheitsstudie -DOGS (32) and the Heinz Nixdorf Recall Studies 1-3 (HNR1-3) (33) . The Dutch sample consisted of 179 AgP cases who were drawn from across The Netherlands and previously described (30) . The Dutch control sample consisted of 2,891 (1,453 males 1,438 females), being individuals from the B-Proof Study (34) . The Turkish AgP sample consisted of 220 cases, which we recruited across Turkey. This sample, along with 75 controls, which we recruited at the same locations, was previously described (30) ; the controls were described in (35) .
CP cases and controls. The German CP cases were described in detail in (6) . In brief, subjects within the first vs. the third tercile of the study population based on the number of proximal sites with AL !4 mm were opposed. Individuals aged >60 years were manually excluded from the analysis to increase the statistical power by enriching the case sample with early-onset phenotypes, which are generally considered to be caused to a larger extent by genetic risk factors. Based on these criteria, the sample consisted of 993 CP cases and 1,419 controls, which were genotyped either with the Affymetrix Genome-Wide Human SNP Array 6.0 or the Illumina Human Omni 2.5 array.
Statistical power calculation. The statistical power was calculated with the PS Power and Sample Size Program (36) . With the given sample sizes, the probability of exposure among controls is 20% and if the true OR for disease in exposed subjects relative to unexposed subjects is 1.3, we were able to reject the null hypothesis that the OR ¼ 1 with a probability (power) ¼ 0.93 for AgP and 0.75 of for CP.
Ethics statement
The AgP studies have been approved by the ethics commission of the medical faculty of the Christian-Albrechts-Universit€ at zu Kiel, Germany (Vote for cases: A 156/03, Vote for controls: B 231/ 98). The protocol of the CP study has been approved by the medical ethics committee of the University of Greifswald. Oral and written informed consents were obtained. All clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki.
Genotyping
Genotyping of the GER and NL AgP cases and controls was performed on an IScan system at the Institute of Clinical Molecular Biology (ICMB), Christian-Albrechts-University (CAU) Kiel, Germany, according to manufacturer's instructions. The AgP cases and controls were genotyped on Omni Bead Chips (Illumina, USA). The specific type of bead chip, which was used for each sample is summarized in Supplementary Material, Table S10 .
Genotyping of the Turkish AgP cases and of 75 controls was carried out with iPLEX assays (Sequenom, San Diego, CA, USA), which were designed by the AssayDesigner v.3.1 software (Sequenom). Assay details are available from the authors upon request. Genotyping was performed at the ICMB, CAU Kiel, using Sequenom MassARRAY iPLEX GOLD chemistry according to standard protocols. SpectroCHIPs were analyzed in automated mode by a MassArray MALDI-TOF Compact System 2 with a solid-phase laser mass spectrometer (Bruker Daltonics, Bremen, Germany), called with the real-time SpectroCaller algorithm, and analyzed using the Sequenom SpectroTyper analyzer software v.4.0.20.65 (Sequenom, San Diego, CA, USA). SNPs rs4970469 (nearest genes NUDC and TRNP1) and rs10238400 (nearest genes RPL10P11 and GNAI1, were genotyped on a 7900HT Fast Real-Time PCR System at the ICMB, CAU Kiel, on 384-well plates using TaqMan assays hCV3230478 and hCV11216204, respectively (Thermo Fisher Scientific, USA), as recently described (37) .
The Turkish GWAS controls (N ¼ 489) were genotyped on HumanOmni1-Quad BeadChip human array (Illumina, USA) as described before (35) .
Quality control and filtering
Prior to the GWAS analysis, we applied several quality control (QC) steps on the GER and NL AgP cases and controls using the software PLINK v1.07 (38) , which reduced the number of SNPs and individuals as shown in the detailed summary of the QC and filtering steps in Supplementary Material, Table S4 . Firstly, we imputed sex for individuals with missing sex information and performed a sex check on the remaining individuals. Due to unclear imputation and sex check results eleven, three, and one individuals were excluded from DOGS, HNR-2 and NL-Cont, respectively. We excluded SNPs from the sex chromosomes. The remaining SNPs were lifted over to the human reference genome version GRCh37/hg19. SNP identifiers were updated to the current reference SNP ID (rsID) using the Ensembl Variation Database v84 (39)sub-cohort separately, we excluded SNPs with minor allele frequency (MAF) < 1%, deviations (P value < 10 À4 )
from Hardy-Weinberg equilibrium (HWE) or genotype call rates < 98%, in the respective order. Next, we used 1000G Phase 3 data of Northern Europeans from Utah (1000GP3-CEU) to flip all genotypes on the forward strand (40) . SNPs with unclear strand direction were removed. A threshold of > 98% for the genotyping call rate per individual resulted in a loss of eleven cases and one control in the German AgP cases, and two cases and 15 controls in Dutch sample. A threshold of > 98% for the genotyping call rate per individual resulted in a loss of 11 cases and one control in the German AgP cases, and two cases and 15 controls in Dutch sample. Lastly, we investigated population stratification by calculating pairwise identity-by-state (IBS) and identity-by-descent (IBD) estimates on a subset of SNPs (100% genotype call rate and MAF > 5%). 145 (22 cases and 43 controls in GER, four cases and 75 controls in NL duplicates and individuals with familial relationships were removed using the constraint "PI_HAT ! 0.125 or DST > 0. Figs S1 and S2 ). In addition, we evaluated the effects of population stratification for GER and NL separately, by using the additive genetic model and the genomic inflation factor (k) function of the R package GenABEL (41) . This resulted in k ¼ 1.08 for GER and k ¼ 1.01 for NL, suggesting the population stratification was only negligible for NL. Therefore, we adjusted for MDS components of the filtered cohort and preformed association tests starting with MDS components 1, then 1 and 2; 1, 2 and 3; etc., as covariates. Examining the first ten MDS components, we observed that components 1 to 6 resulted in the lowest genomic inflation factor (k ¼ 1,04). This combination was assigned as additional covariates for GER.
Genotype imputation
Post QC genotypes were converted from Plink BED/BIM/FAM format to Oxford Gen/Sample format with GTOOL v0.7.5 in order to estimate the haplotypes with the software ShapeIt v2 (42) . Then the imputation of ungenotyped SNPs was carried out for the resulting haplotypes using the 1000G Phase 3 data and Impute v2 (43) .
Association testing and meta-analysis
Associations of SNPs with AgP in both GER and NL were tested with SNPTEST v2.5.2 using an additive model (with 1 degree of freedom) with the binary variables sex and smoking status (never smoked ¼ 0, ever smoked ¼ 1) as covariates (44) . For GER we additionally adjusted for the first 6 MDS components. SNPs in the output were excluded by imputation quality (column frequentist_add_info) < 0.9, average maximal posterior probability (column average_maximum_posterior_call) < 0.9, MAF < 5% in cases or controls and deviation from HWE (P value < 10 À4 ) in controls. A total of 6,568,093 and 6,475,582 (6,374,298 intersecting) genotyped and imputed autosomal SNPs from GER and NL were then combined in a discovery meta-analysis. Level of statistical heterogeneity was measured using Cochran's Q and the I-square (I 2 ) statistic (45) . For the discovery meta-analysis as well as subsequent meta-analyses using validation and replication samples, SNPs having P(Q) < 0.05 and I 2 > 0.5, i.e. a high amount of heterogeneity, were meta-analyzed with the random effects model, for the remaining SNPs the fixed effects model was used. The potential impact of population stratification as well as the overall significance of the GWAS results were evaluated using quantilequantile plots and genomic inflation factors (k).
Selection of SNPs for validation and replication
We selected SNPs to validate their association with CP, which complied with the following criteria in the combined AgP casecontrol sample: (1) combined P value (GER þ NL; P meta < 10
À5
unadjusted for MDS components (we preassigned this significance threshold as being indicative of suggestive evidence of association with disease (46); (2) P meta < P ger and P meta < P nl ; (3) SNPs within strong linkage disequilibrium (LD; r 2 > 0.8 in 1000GP3-EUR) show association with AgP (P meta < 10 À3 ) in the combined sample. (4) SNPs < 500 kb distance to each other among the remaining SNPs were clumped into linked loci and the SNP with the lowest P value was kept. Imputed genotype information was lacking in the validation cohort of CP for seven SNPs, and we attempted to replace these seven with the best surrogates based on linkage disequilibrium (LD) using genotypes of the European reference population (EUR) of 1000 genomes. Lead SNP rs3830904 was replaced by rs2144815, which showed complete LD (r 2 ¼ 1 
Relationship with other traits analyses
For each of the 16 loci in our top hit list we extracted all traits within position of the top SNP þ/-200kb from the NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog, January 2017) (51) . In a LD score regression analysis, the genetic correlation between adjusted summary statistics of AgP-GER-NL and 219 other traits was computed using LD Hub (52) .
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